categorized SCLC patients into four subtypes based on expression profiles of transcriptional factors (ASCL1, NEUROD1, POU2F3, and YAP1), with each type exhibiting a distinct expression pattern and sensitivity to different therapeutic drugs (11). This evidence concerns the gene POU2F3 and small cell lung carcinoma.